69,70 Patients in a phase 2 clinical trial employing curcumin in 21 patients with advanced pancreatic cancer demonstrated clinical indications of tumor regression after receiving 8 g/day of curcumin orally for 8 weeks
The "gradual decline" group (approximately 40-50% of users) represents modal experience where benefits slowly regress toward pre-treatment baseline over 4-8 months, typically affecting users who completed shorter treatment courses (2-4 months), used lower concentrations or inconsistent application, possessed moderate to severe baseline skin damage requiring ongoing support, maintained adequate but not optimal complementary skincare, experienced significant lifestyle stressors affecting skin health including poor sleep or high stress, and faced genetic or age-related collagen production limitations
Ongoing studies continue to explore how these pathways contribute to tissue maintenance and normal physiological repair processes
au bng nghim trng, dn n cc bin chng nguy him nh tc phi, nhim trng huyt do phng php thc hin khng ng k thut
No experimental datasets were generated during the current study
It's like you're in a group where everybody else is working hard, too, and it's contagious
